JPMorgan upgrades Replimune stock rating on FDA resubmission path

JPMorgan upgrades Replimune stock rating on FDA resubmission path

Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.